NEFL (Neurofilament Light Polypeptide) encodes the light chain subunit of neurofilaments, the most abundant intermediate filament in neurons of the central and peripheral nervous systems. Neurofilaments are essential for maintaining axonal caliber, supporting myelinated axons, and enabling rapid nerve conduction. NEFL is also one of the most extensively studied biomarkers for neurodegenerative diseases, with blood and CSF neurofilament light chain (NfL) levels reflecting the degree of axonal injury across Alzheimer's disease, Parkinson's disease, ALS, and numerous other neurological conditions.
| Property |
Value |
| Symbol |
NEFL |
| Full Name |
Neurofilament Light Polypeptide |
| Chromosomal Location |
8p21.2 |
| NCBI Gene ID |
4747 |
| OMIM ID |
162280 |
| Ensembl ID |
ENSG00000104825 |
| UniProt ID |
P07196 |
| Protein Length |
543 amino acids |
| Molecular Weight |
~61.5 kDa |
| Expression |
CNS and PNS neurons (axons) |
| Associated Diseases |
ALS, CMT, AD, PD, MS, FTD, Huntington's |
¶ Gene Structure and Expression
The NEFL gene spans approximately 11.5 kb on chromosome 8p21.2 and contains 4 exons. The gene encodes a single polypeptide that is expressed predominantly in neurons during late embryonic and postnatal development, with expression maintained throughout adult life.
NEFL is expressed in:
- Central nervous system: Large pyramidal neurons of the cortex, motor neurons of the spinal cord, Purkinje cells of the cerebellum, retinal ganglion cells, dopaminergic neurons of the substantia nigra
- Peripheral nervous system: Large myelinated fibers of peripheral nerves, sensory and motor neurons
- Non-neuronal: Low or absent expression in glia, non-neural tissues
Expression is regulated by neuronal activity and trophic factors. Kinesin-mediated axonal transport moves NEFL-containing neurofilaments from the cell body into the axonal compartment.
Neurofilaments are assembled from three subunits in a heteropolymer structure:
| Subunit |
Gene |
Size |
Features |
| NFL (Light) |
NEFL |
~61 kDa |
Tail domain with Lys-Ser-Pro (KSP) motifs |
| NFM (Medium) |
NEFM |
~102 kDa |
Additional tail phosphorylation sites |
| NFH (Heavy) |
NEFH |
~112 kDa |
Longest tail, highest phosphorylation |
NFL serves as the structural backbone, with NFM and NFH assembling along NFL tetramers to form the mature filament. Each neurofilament is approximately 10 nm in diameter and can extend to many micrometers within axons.
¶ Domain Structure
The NEFL protein consists of three domains:
- N-terminal head region (~80 aa): Non-alpha-helical, contains phosphorylation sites and regulatory sequences
- Central alpha-helical rod domain (~310 aa): Highly conserved, mediates filament assembly through coiled-coil interactions
- C-terminal tail domain (~150 aa): Unique to NFL, contains KSP repeat motifs and phosphorylation sites
Phosphorylation of the tail domain regulates neurofilament spacing in axons, affecting axonal caliber.
Neurofilament assembly follows this pathway:
- NFL tetramer formation: Two NFL dimers associate via their rod domains to form tetramers
- Unit-length filament formation: Tetramers align to form short protofilaments
- Filament elongation: Protofilaments anneal end-to-end and side-by-side to form mature neurofilaments
- Axonal transport: Neurofilaments are transported down axons via slow axonal transport (0.5-3 mm/day)
Neurofilaments provide structural support and maintain axonal caliber:
- Mechanical support: Resists compressive and tensile forces on axons
- Axonal diameter regulation: Neurofilament content directly determines axonal diameter (larger axons = more neurofilaments)
- Myelin attachment: Neurofilament-filled axons provide the scaffold for myelin wrapping by Schwann cells (PNS) or oligodendrocytes (CNS)
- Fast axonal transport support: Neurofilaments interact with motors for organelle transport
Axonal caliber, maintained by neurofilaments, directly determines nerve conduction velocity:
- Large-diameter myelinated axons conduct at 40-120 m/s
- Small unmyelinated fibers conduct at 0.5-2 m/s
- NEFL mutations causing smaller axonal caliber → slowed conduction → neuropathy
During development, neurofilament expression supports:
- Axon growth and pathfinding
- Synapse formation and maintenance
- Dendritic arborization
- Neuronal survival
NfL is one of the most extensively validated biomarkers for ALS:
- Diagnostic biomarker: Elevated NfL in CSF (mean ~3,500 pg/mL vs ~600 pg/mL in controls) and blood
- Prognostic marker: Higher NfL levels correlate with faster disease progression and shorter survival
- Biomarker for clinical trials: Used as endpoint to measure treatment effects on neurodegeneration rate
- Disease progression tracking: NfL levels increase over time as motor neurons die
- Differential diagnosis: Helps distinguish ALS from mimics (e.g., multifocal motor neuropathy)
- Genetics: Rare NEFL mutations cause ALS with typical TDP-43 pathology
Mechanism: Motor neuron death releases NfL into extracellular space, where it enters CSF and blood.
NEFL mutations cause autosomal dominant intermediate CMT:
- CMT type 1F (NF-L): Intermediate or predominantly demyelinating phenotype
- CMT type 2E (NF-L): Predominantly axonal neuropathy
- Clinical features: Distal weakness, sensory loss, foot deformities, slowed nerve conduction
- Pathology: Reduced axonal caliber, loss of large myelinated fibers, neurofilament accumulation
- Mechanism: Mutations disrupt neurofilament assembly and axonal transport
- Genotype-phenotype: Over 50 pathogenic variants described (missense, nonsense, splice site)
NfL is elevated in AD and reflects the axonal injury component of the disease:
- Diagnostic value: NfL in CSF (mean ~400 pg/mL in AD vs ~200 pg/mL controls)
- Progression marker: Higher NfL correlates with faster cognitive decline and brain atrophy
- Cognitive correlation: NfL levels predict rate of MMSE decline
- Braak stage correlation: NfL elevation tracks with neurofibrillary tangle burden
- Comparison to other markers: NfL rises later than p-tau181/217 but before clinical symptoms in some cases
- Interaction with tau: NfL and p-tau provide complementary information about neurodegeneration vs tangle pathology
NfL serves as a biomarker of nigrostriatal degeneration in PD:
- Diagnostic utility: Elevated serum NfL in PD vs controls (mean ~20 pg/mL vs ~12 pg/mL)
- Progression marker: Higher NfL correlates with worse UPDRS scores and faster progression
- Atypical PD differentiation: Much higher NfL in PSP and MSA vs typical PD
- Substantia nigra involvement: Reflects dopaminergic neuron loss in the SNc
- Prodromal potential: Elevated NfL may detect axonal injury before motor diagnosis
- Comparison to alpha-synuclein: NfL and alpha-synuclein seed amplification provide complementary information
NfL is widely used as a biomarker in MS:
- Disease activity marker: Elevated NfL during active relapses and in progressive MS
- Treatment monitoring: NfL levels decrease with effective immunomodulatory therapy
- Prognostic value: Higher baseline NfL predicts worse long-term outcomes
- Conversion prediction: NfL helps predict CIS to clinically definite MS conversion
- Dark visible lesions: NfL elevation reflects the acute axonal injury visible as black holes on MRI
¶ Frontotemporal Dementia and Other Dementias
NfL elevation across dementia spectrum:
- FTD subtypes: Elevated in behavioral variant FTD, semantic variant PPA, progressive supranuclear palsy, corticobasal syndrome
- AD vs FTD differentiation: NfL generally higher in FTD than AD, complements tau markers
- Progression rate: Higher NfL predicts faster clinical decline in FTD
- ALS-FTD overlap: Very high NfL in patients with both motor and cognitive symptoms
| Method |
Sample |
Advantages |
Limitations |
| Simoa (Single molecule array) |
Blood, CSF |
Ultra-sensitive, automatable |
Requires specialized equipment |
| ELISA |
Blood, CSF |
Widely available |
Lower sensitivity than Simoa |
| Electrochemiluminescence |
Blood, CSF |
High throughput |
Moderate sensitivity |
| Lumipulse |
CSF |
Automated, clinical lab use |
CSF only |
| Population |
Serum NfL (pg/mL) |
CSF NfL (pg/mL) |
| Young adults (<40) |
3-12 |
150-500 |
| Middle age (40-60) |
8-25 |
300-800 |
| Elderly (>60) |
12-40 |
500-1500 |
| ALS patients |
50-300 |
1500-8000 |
| AD patients |
15-60 |
300-1500 |
NfL biomarker applications:
- Diagnosis: Support differential diagnosis in unclear cases
- Prognosis: Predict disease progression rate and survival
- Monitoring: Track treatment response in clinical trials and clinical practice
- Screening: Identify axonal injury in at-risk populations
- Enrollment: Enrich clinical trials with faster progressors
¶ Limitations and Caveats
- Age dependence: NfL increases with age, requiring age-adjusted thresholds
- Non-specific: Elevated NfL reflects axonal injury from any cause (trauma, stroke, infection)
- Variable kinetics: Different diseases release NfL at different rates
- Kidney function: NfL is cleared by the kidney; renal impairment elevates serum NfL
- Longitudinal variability: Single measurements may not reflect disease trajectory
Approaches to protect neurons from NfL-related pathology:
- TDP-43 modulators: Target upstream events causing neurofilament accumulation in ALS
- Axonal transport enhancers: Improve delivery of neurofilaments and organelles along axons
- Neuroinflammation reduction: Lower microglial activation to reduce secondary axonal injury
- Anti-aggregation agents: Prevent toxic neurofilament aggregates from forming
| Trial |
Indication |
NfL use |
Phase |
| Pharmatherapeutics |
ALS |
Primary endpoint |
II |
| TPN-101 |
ALS/FTD |
Secondary endpoint |
I |
| Reldesemtiv |
ALS |
Biomarker |
IIb |
- Axonal atrophy: Reduced axonal caliber without neurofilament content
- Slowed conduction: Reduced nerve conduction velocity
- Surprisingly mild phenotype: Mice survive and breed despite major structural deficits
- Compensatory upregulation: Other cytoskeletal proteins (tau, actin) upregulated
- Late-onset ataxia: Progressive gait instability resembling CMT
- Axonal pathology: Accumulation and aggregation of mutant neurofilaments
- Demyelination secondary: Myelin degeneration secondary to axonal defects
- Models human disease: Recapitulates key features of NEFL-associated neuropathy
Key areas of ongoing research include:
- Fluid biomarker combinations: NfL combined with p-tau217, GFAP, NfH for improved accuracy
- Blood-based neurofilament assays: Development of point-of-care testing for clinical use
- Neurofilament heavy chain (NfH): Complementary biomarker with potentially different kinetics
- Age-adjusted reference values: Establishing population norms across age groups
- Treatment response monitoring: Using NfL to guide therapeutic decisions in real time
- Genetic forms of ALS/CMT: Understanding how NEFL mutations cause disease
NEFL encodes the light chain of neurofilaments, the primary cytoskeletal protein of axons. Neurofilament maintenance is essential for axonal caliber and nerve conduction velocity, and disruption of NEFL causes Charcot-Marie-Tooth disease. When neurons die in neurodegenerative diseases, neurofilament light chain is released into biological fluids, making NfL one of the most valuable biomarkers for ALS, Alzheimer's disease, Parkinson's disease, MS, FTD, and other neurological conditions. Blood NfL testing is now widely used in clinical trials and is moving toward clinical practice, offering a window into the degree of ongoing axonal injury in real time.